As of 4:00pm ET
| -0.07 / -3.47%|
The 2 analysts offering 12-month price forecasts for Repros Therapeutics Inc have a median target of 2.75, with a high estimate of 3.50 and a low estimate of 2.00. The median estimate represents a +41.03% increase from the last price of 1.95.
The current consensus among 3 polled investment analysts is to Hold stock in Repros Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.